No Data
No Data
iBio (IBIO.US) has obtained the license for the iBio-600 antibody, which will expand the cardiac metabolism and obesity treatment program.
iBio (IBIO.US) announced on Thursday that it has obtained the license for long-acting myostatin-inhibitory antibodies from AstralBio, thereby expanding its cardiovascular metabolism and obesity treatment development projects.
Express News | Ibio Inc: Astralbio Eligible for Development & Commercialization Milestone Payments Totaling up to $28 Mln
Express News | Ibio Inc: Plans to Enter Into Clinical Investigation in Obesity and Cardiometabolic Disorders in 2026
IBio Expands Obesity Program With $750K Upfront Payment and $28M AstralBio Partnership
IBio Expands Cardiometabolic and Obesity Program With Anti-Myostatin Antibody Discovered Using Its Proprietary Platform, In-Licensed From AstralBio
IBio Inc. Stock Rises Tuesday, Outperforms Market